Baidu
map

消化指南

订阅

MedSci主页 / 所有栏目 / 消化指南

2021 AGA临床实践指南：中重度管腔和肛周瘘管克罗恩病的药物治疗

2021-05-30 美国胃肠病协会 Gastroenterology.2021 Jun;160(7):2496-2508.

克罗恩病

2021年,美国胃肠病协会(AGA)发布了中重度管腔和肛周瘘管克罗恩病的药物治疗指南，克罗恩病（CD）是慢性炎症性肠病的一种，如果得不到充分控制，其发病率很高。本文主要针对中重度管腔和肛周瘘管克罗恩病

中文标题：

2021 AGA临床实践指南：中重度管腔和肛周瘘管克罗恩病的药物治疗

英文标题：

AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease

发布机构：

美国胃肠病协会

发布日期：

2021-05-30

简要介绍：

2021年,美国胃肠病协会(AGA)发布了中重度管腔和肛周瘘管克罗恩病的药物治疗指南，克罗恩病（CD）是慢性炎症性肠病的一种，如果得不到充分控制，其发病率很高。本文主要针对中重度管腔和肛周瘘管克罗恩病的药物治疗提供循证指导建议。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 AGA临床实践指南：中重度管腔和肛周瘘管克罗恩病的药物治疗.pdf)] GetToolGuiderByIdResponse(projectId=1, id=cda1d1c00211e2d4, title=2021 AGA临床实践指南：中重度管腔和肛周瘘管克罗恩病的药物治疗, enTitle=AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease, guiderFrom=Gastroenterology.2021 Jun;160(7):2496-2508., authorId=0, author=, summary=2021年,美国胃肠病协会(AGA)发布了中重度管腔和肛周瘘管克罗恩病的药物治疗指南，克罗恩病（CD）是慢性炎症性肠病的一种，如果得不到充分控制，其发病率很高。本文主要针对中重度管腔和肛周瘘管克罗恩病, cover=https://img.medsci.cn/2021628/1624820247075_2020535.jpg, journalId=0, articlesId=null, associationId=102, associationName=美国胃肠病协会, associationIntro=美国胃肠病协会成立于1897年,已包括来自全球各地17000个成员参与消化所有方面的研究、实践和前沿。提供各项关于胃肠道疾病的指南和研究，发布两本期刊，都为月刊，每年5月份会举行年会。, copyright=0, guiderPublishedTime=Sun May 30 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2021年,美国胃肠病协会(AGA)发布了中重度管腔和肛周瘘管克罗恩病的药物治疗指南，克罗恩病（CD）是慢性炎症性肠病的一种，如果得不到充分控制，其发病率很高。本文主要针对中重度管腔和肛周瘘管克罗恩病的药物治疗提供循证指导建议。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=984, tagName=克罗恩病)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=984, guiderKeyword=克罗恩病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=1, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8978, appHits=158, showAppHits=0, pcHits=941, showPcHits=8820, likes=1, shares=14, comments=9, approvalStatus=1, publishedTime=Mon Jun 28 02:57:37 CST 2021, publishedTimeString=2021-05-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Mon Jun 28 02:57:32 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Fri Jan 05 17:32:28 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 AGA临床实践指南：中重度管腔和肛周瘘管克罗恩病的药物治疗.pdf)])
2021 AGA临床实践指南：中重度管腔和肛周瘘管克罗恩病的药物治疗.pdf
下载请点击：
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1075651, encodeId=a7dd10e565100, content=学习，, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160929/IMG57EBFB2F217CC3250.jpg, createdBy=e8381958770, createdName=14号射手, createdTime=Wed Dec 01 02:08:53 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075650, encodeId=23bd10e565045, content=学习，, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160929/IMG57EBFB2F217CC3250.jpg, createdBy=e8381958770, createdName=14号射手, createdTime=Wed Dec 01 02:08:39 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012186, encodeId=2629101218602, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pziagHzC55dMtRCa2MctUKyALiaOcX7mwXPkibxxyflEicVZ1cfae4dNMMuHbaKlgrZxduclGv5iaeYCWssY9BjyOtw/132, createdBy=81442483907, createdName=达芬奇, createdTime=Fri Aug 27 22:21:20 CST 2021, time=2021-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009563, encodeId=c52f10095634a, content=努力学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1af15132182, createdName=1465ac12m61暂无昵称, createdTime=Thu Aug 19 22:13:51 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003250, encodeId=38431003250f6, content=很有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e655558424, createdName=于药师, createdTime=Wed Jul 28 09:51:14 CST 2021, time=2021-07-28, status=1, ipAttribution=)]
    2021-12-01 14号射手

    学习，

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1075651, encodeId=a7dd10e565100, content=学习，, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160929/IMG57EBFB2F217CC3250.jpg, createdBy=e8381958770, createdName=14号射手, createdTime=Wed Dec 01 02:08:53 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075650, encodeId=23bd10e565045, content=学习，, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160929/IMG57EBFB2F217CC3250.jpg, createdBy=e8381958770, createdName=14号射手, createdTime=Wed Dec 01 02:08:39 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012186, encodeId=2629101218602, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pziagHzC55dMtRCa2MctUKyALiaOcX7mwXPkibxxyflEicVZ1cfae4dNMMuHbaKlgrZxduclGv5iaeYCWssY9BjyOtw/132, createdBy=81442483907, createdName=达芬奇, createdTime=Fri Aug 27 22:21:20 CST 2021, time=2021-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009563, encodeId=c52f10095634a, content=努力学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1af15132182, createdName=1465ac12m61暂无昵称, createdTime=Thu Aug 19 22:13:51 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003250, encodeId=38431003250f6, content=很有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e655558424, createdName=于药师, createdTime=Wed Jul 28 09:51:14 CST 2021, time=2021-07-28, status=1, ipAttribution=)]
    2021-12-01 14号射手

    学习，

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1075651, encodeId=a7dd10e565100, content=学习，, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160929/IMG57EBFB2F217CC3250.jpg, createdBy=e8381958770, createdName=14号射手, createdTime=Wed Dec 01 02:08:53 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075650, encodeId=23bd10e565045, content=学习，, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160929/IMG57EBFB2F217CC3250.jpg, createdBy=e8381958770, createdName=14号射手, createdTime=Wed Dec 01 02:08:39 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012186, encodeId=2629101218602, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pziagHzC55dMtRCa2MctUKyALiaOcX7mwXPkibxxyflEicVZ1cfae4dNMMuHbaKlgrZxduclGv5iaeYCWssY9BjyOtw/132, createdBy=81442483907, createdName=达芬奇, createdTime=Fri Aug 27 22:21:20 CST 2021, time=2021-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009563, encodeId=c52f10095634a, content=努力学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1af15132182, createdName=1465ac12m61暂无昵称, createdTime=Thu Aug 19 22:13:51 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003250, encodeId=38431003250f6, content=很有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e655558424, createdName=于药师, createdTime=Wed Jul 28 09:51:14 CST 2021, time=2021-07-28, status=1, ipAttribution=)]
    2021-08-27 达芬奇

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1075651, encodeId=a7dd10e565100, content=学习，, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160929/IMG57EBFB2F217CC3250.jpg, createdBy=e8381958770, createdName=14号射手, createdTime=Wed Dec 01 02:08:53 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075650, encodeId=23bd10e565045, content=学习，, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160929/IMG57EBFB2F217CC3250.jpg, createdBy=e8381958770, createdName=14号射手, createdTime=Wed Dec 01 02:08:39 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012186, encodeId=2629101218602, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pziagHzC55dMtRCa2MctUKyALiaOcX7mwXPkibxxyflEicVZ1cfae4dNMMuHbaKlgrZxduclGv5iaeYCWssY9BjyOtw/132, createdBy=81442483907, createdName=达芬奇, createdTime=Fri Aug 27 22:21:20 CST 2021, time=2021-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009563, encodeId=c52f10095634a, content=努力学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1af15132182, createdName=1465ac12m61暂无昵称, createdTime=Thu Aug 19 22:13:51 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003250, encodeId=38431003250f6, content=很有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e655558424, createdName=于药师, createdTime=Wed Jul 28 09:51:14 CST 2021, time=2021-07-28, status=1, ipAttribution=)]
    2021-08-19 1465ac12m61暂无昵称

    努力学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1075651, encodeId=a7dd10e565100, content=学习，, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160929/IMG57EBFB2F217CC3250.jpg, createdBy=e8381958770, createdName=14号射手, createdTime=Wed Dec 01 02:08:53 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075650, encodeId=23bd10e565045, content=学习，, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160929/IMG57EBFB2F217CC3250.jpg, createdBy=e8381958770, createdName=14号射手, createdTime=Wed Dec 01 02:08:39 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012186, encodeId=2629101218602, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pziagHzC55dMtRCa2MctUKyALiaOcX7mwXPkibxxyflEicVZ1cfae4dNMMuHbaKlgrZxduclGv5iaeYCWssY9BjyOtw/132, createdBy=81442483907, createdName=达芬奇, createdTime=Fri Aug 27 22:21:20 CST 2021, time=2021-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009563, encodeId=c52f10095634a, content=努力学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1af15132182, createdName=1465ac12m61暂无昵称, createdTime=Thu Aug 19 22:13:51 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003250, encodeId=38431003250f6, content=很有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e655558424, createdName=于药师, createdTime=Wed Jul 28 09:51:14 CST 2021, time=2021-07-28, status=1, ipAttribution=)]
    2021-07-28 于药师

    很有用

    0

相关指南

2020 ASCRS临床实践指南：克罗恩病的手术治疗

美国结肠和直肠外科医师学会(ASCRS,American Society of Colon and Rectal Surgeons) · 2020-07-22

2020 SICCR炎症性肠病立场声明：克罗恩病

意大利结直肠外科学会(SICCR,Italian society of colorectal surgery) · 2020-03-14

2020 全球IBD干预组共识声明：克罗恩病狭窄内镜治疗指南

国外消化科相关专家小组（统称） · 2020-01-16

2019 NICE指南：克罗恩病的管理

暂未更新 · 2019-05-03

2019 CAG临床实践指南：儿童腔内克罗恩病的医学治疗

加拿大胃肠病学协会(CAG,The Canadian Association of Gastroenterology) · 2019-07-10

2019 CAG临床实践指南：腔内克罗恩病的管理

加拿大胃肠病学协会(CAG,The Canadian Association of Gastroenterology) · 2019-07-15

拓展阅读

2016NICE：克罗恩病管理指南更新

暂未更新 · 2016-06-12

2016 ECCO欧洲循证共识：克罗恩病的诊断管理

暂未更新 · 2016-09-22

2017 ESPGHAN指南：儿童克罗恩病的手术治疗

欧洲儿科胃肠病学、肝病学和营养协会(ESPGHAN,European Society for Paediatric Gastroenterology, Hepatology, and Nutrition) · 2017-03-06

2016 AGA指南：外科手术后克罗恩病的管理

美国胃肠病协会(AGA,American Gastroenterological Association) · 2016-11-10

2017 ACPGBI共识：克罗恩病肛周瘘管的手术治疗

大不列颠及爱尔兰肛肠协会(ACPGBI,Association of Coloproctology of Great Britain and Ireland) · 2017-04-07

2017 ECCO/ESCP共识：克罗恩病的手术治疗

暂未更新 · 2017-05-11

Baidu
map
Baidu
map
Baidu
map